These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 28143387

  • 1. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
    Vrontaki E, Melagraki G, Voskou S, Phylactides MS, Mavromoustakos T, Kleanthous M, Afantitis A.
    Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H, Raj U, Gupta S, Varadwaj PK.
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [Abstract] [Full Text] [Related]

  • 4. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA, Sonwane GM.
    Curr Drug Discov Technol; 2020 Oct; 17(2):213-224. PubMed ID: 30210004
    [Abstract] [Full Text] [Related]

  • 5. Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and in Vitro Validation in Drug Resistant Chronic Myeloid Leukemia Cells.
    Melge AR, Parate S, Pavithran K, Koyakutty M, Mohan CG.
    J Chem Inf Model; 2022 Feb 28; 62(4):1126-1146. PubMed ID: 35172577
    [Abstract] [Full Text] [Related]

  • 6. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
    Shukla S, Kouanda A, Silverton L, Talele TT, Ambudkar SV.
    Mol Pharm; 2014 Jul 07; 11(7):2313-22. PubMed ID: 24865254
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK, Jin H, Seo SH, Bang EK, Keum G.
    Eur J Med Chem; 2020 Dec 01; 207():112710. PubMed ID: 32961435
    [Abstract] [Full Text] [Related]

  • 8. vHTS, 3-D Pharmacophore, QSAR and Molecular Docking Studies for the Identification of Phyto-derived ATP-Competitive Inhibitors of the BCR-ABL Kinase Domain.
    Metibemu DS, Oyeneyin OE, Metibemu AO, Adeniran OY, Omotuyi IO.
    Curr Drug Discov Technol; 2022 Dec 01; 19(2):e021221198480. PubMed ID: 34856909
    [Abstract] [Full Text] [Related]

  • 9. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
    Park H, Hong S, Kim J, Hong S.
    J Am Chem Soc; 2013 Jun 05; 135(22):8227-37. PubMed ID: 23679864
    [Abstract] [Full Text] [Related]

  • 10. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.
    Cui J, Fu R, Zhou LH, Chen SP, Li GW, Qian SX, Liu S.
    Bioorg Med Chem Lett; 2013 Apr 15; 23(8):2442-50. PubMed ID: 23473682
    [Abstract] [Full Text] [Related]

  • 11. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI, Ozturk SE, Ali TFS, Radwan MO, Tateishi H, Koga R, Ocak Z, Can M, Otsuka M, Fujita M.
    Biol Pharm Bull; 2018 Apr 01; 41(4):570-574. PubMed ID: 29386476
    [Abstract] [Full Text] [Related]

  • 12. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J.
    J Med Chem; 2016 Mar 10; 59(5):1984-2004. PubMed ID: 26789553
    [Abstract] [Full Text] [Related]

  • 13. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
    El Rashedy AA, Olotu FA, Soliman MES.
    Chem Biodivers; 2018 Mar 10; 15(3):e1700533. PubMed ID: 29325229
    [Abstract] [Full Text] [Related]

  • 14. New insights into small-molecule inhibitors of Bcr-Abl.
    Schenone S, Bruno O, Radi M, Botta M.
    Med Res Rev; 2011 Jan 10; 31(1):1-41. PubMed ID: 19714578
    [Abstract] [Full Text] [Related]

  • 15. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.
    Schenone S, Brullo C, Botta M.
    Curr Med Chem; 2010 Jan 10; 17(13):1220-45. PubMed ID: 20166937
    [Abstract] [Full Text] [Related]

  • 16. Bcr-Abl tyrosine kinase inhibitors: a patent review.
    Desogus A, Schenone S, Brullo C, Tintori C, Musumeci F.
    Expert Opin Ther Pat; 2015 Apr 10; 25(4):397-412. PubMed ID: 25656651
    [Abstract] [Full Text] [Related]

  • 17. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
    Koroleva EV, Kornoushenko YV, Karpenko AD, Bosko IP, Siniutsich JV, Ignatovich ZV, Andrianov AM.
    J Biomol Struct Dyn; 2023 Jun 10; 41(9):4065-4080. PubMed ID: 35470777
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K, Fu LW.
    Crit Rev Oncol Hematol; 2015 Mar 10; 93(3):277-92. PubMed ID: 25500000
    [Abstract] [Full Text] [Related]

  • 19. Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia.
    Parcha P, Sarvagalla S, Madhuri B, Pajaniradje S, Baskaran V, Coumar MS, Rajasekaran B.
    Chem Biol Drug Des; 2017 Oct 10; 90(4):596-608. PubMed ID: 28338290
    [Abstract] [Full Text] [Related]

  • 20. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.
    Zhang Y, Wu X, Sun X, Yang J, Liu C, Tang G, Lei X, Huang H, Peng J.
    Mini Rev Med Chem; 2024 Oct 10; 24(6):642-663. PubMed ID: 37855278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.